immunologyTariff appliesAnnex III — Jul 31 2026

Rinvoq Tariff Rate & July 31, 2026 Deadline

Rinvoq (Upadacitinib) — manufactured by AbbVie in Germany. Treats rheumatoid arthritis, eczema, crohn's. Typical US retail $6,300 per month.

Tariff breakdown

Applicable rate: 100% (Annex III)
Effective date: 2026-07-31 (98 days away)
Manufacturer: AbbVie
Country of origin: Germany
Annex III?: Yes
Current monthly retail: $6,300

Projected monthly retail, by pass-through scenario

Scenario	Pass-through	New monthly retail	Annual increase
Conservative	30%	$8,190	+$22,680
Likely	50%	$9,450	+$37,800
Worst case	100%	$12,600	+$75,600

Scenarios based on historical brand-pharma cost-shock pass-through. Not a forecast.

HTS classification

HTS 3004.90.9299

Upadacitinib tablets, retail packaging, HTS 3004.90. AbbVie manufactures in Germany — subject to the 100% tariff.

Source: USITC Harmonized Tariff Schedule, 2026 Revision 2 — hts.usitc.gov

Alternatives: generics, biosimilars & US-made options

Xeljanz (tofacitinib, Pfizer)

therapeutic alternative

Earlier-generation JAK inhibitor; Pfizer is Annex III, Germany-made — tariff applies.

Olumiant (baricitinib, Eli Lilly)

us made

JAK inhibitor from Eli Lilly — US manufacturing, tariff-exempt.

Humira (adalimumab, AbbVie)

us made

Different mechanism (TNF-alpha inhibitor), US-made in Puerto Rico — tariff-exempt alternative for some Rinvoq indications.

Always consult your prescriber before switching medications. Biosimilars and generics are not interchangeable in every state without physician approval.

FAQ: Rinvoq and the 2026 tariff

Will my Rinvoq prescription cost more after July 31, 2026?

Likely yes. Rinvoq is manufactured in Germany and is not exempt. Our conservative-case scenario assumes 30% pass-through (retail +$1,890/month), our likely-case 50% (+$3,150/month), and worst-case full pass-through (+$6,300/month).

Can I switch to a generic version of Upadacitinib?

No FDA-approved generic of Upadacitinib is widely available in the US as of 2026 Q2. Biosimilars or therapeutic alternatives (listed above) are the practical substitutes.

Is Rinvoq on the Medicare negotiated-price list?

Rinvoq is not among the first-round Medicare-negotiated drugs effective 2026. Check CMS announcements for subsequent negotiation rounds.

Importing pharmaceuticals commercially?

This page covers consumer drug pricing. For business imports (including finished-dose pharmaceuticals), use the full US import tariff calculator with HTS classification and Section 301/232/122 breakdown.

Disclaimer: Informational estimates based on public list prices, the April 2, 2026 Proclamation text, and USITC HTS data. Not medical, legal, or financial advice.

Talk to your doctor, pharmacist, and insurer about your specific medication.